You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NEW YORK – Treadwell Therapeutics said on Friday that its TTK inhibitor CFI-402257 is being studied in three cohorts in the dose expansion portion of a Phase I study, and two of the cohorts will enroll biomarker-defined breast cancer subpopulations.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?Register for Free.
The emergence of cell clones that are resistant to targeted therapies poses a significant issue in the treatment of metastatic melanoma.
Cancer is a complex and heterogeneous disease requiring patient-specific molecular analysis to support treatment decisions.
Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.